Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival
Authors:
Open Access
- 7 October 2021
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 71 (5) , 1157-1165
Abstract
Introduction: Immune checkpoint inhibitors (ICI) are associated with unique immune-related adverse events (irAEs). Immune-related thrombocytopenia (irTCP) is an understudied and poorly understood toxicity; little data are available regarding either risk of irTCP or the effect of irTCP on clinical outcomes of patients treated with ICI. Methods: We conducted a retrospective review of sequential cancer patients treated with ICI between 2011 and 2017 at our institution. All patients who received ICI alone or in combination with other systemic therapy in any line of treatment were included; those with thrombocytopenia ≥ grade 3 at baseline were excluded. We calculated the incidence of ≥ grade 3 irTCP and overall survival (OS). Patient factors associated with irTCP were assessed. Results: We identified 1,038 patients that met eligibility criteria. Overall, 89 (8.6%) patients developed grade ≥ 3 thrombocytopenia; eighteen were attributed to ICI (1.73% overall). Patients who developed grade ≥ 3 irTCP had worse overall survival compared to those whose thrombocytopenia was unrelated to ICI (4.17 vs. 10.8 month; HR. 1.94, 95% CI 1.13, 3.33; log-rank p = 0.0164). Patients with grade ≥ 3 irTCP also had worse survival compared to those without thrombocytopenia (4.17 vs. 13.31 months; HR 2.22, 95% CI 1.36, 3.62; log-rank p = 0.001). The incidence of irTCP appeared lowest among those treated with PD-1/L1 monotherapy (p = 0.059) and was not associated with cancer type, smoking status, age, gender, race, or line of therapy. Conclusions: Unlike other irAEs, we found that irTCP was associated with worse overall survival. The incidence of irTCP appeared lowest among those treated with PD-1/L1 monotherapy.Keywords
Funding Information
- National Institutes of Health (P30CA016058, K12 CA133250)
- Center for Clinical and Translational Science, Ohio State University (UL1TR002733)
This publication has 45 references indexed in Scilit:
- Thrombocytopenia Is Associated With Multi-organ System Failure in Patients With Acute Liver FailureClinical Gastroenterology and Hepatology, 2016
- Thrombocytopenia in adult patients with sepsis: incidence, risk factors, and its association with clinical outcomeJournal of Intensive Care, 2013
- Thrombocytopenia in Adult Cancer Patients Receiving Cytotoxic ChemotherapyDrug Safety, 2011
- Platelets and viruses: an ambivalent relationshipCellular and Molecular Life Sciences, 2009
- Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and managementJournal of Thrombosis and Haemostasis, 2009
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Chemotherapy-Associated ThrombocytopeniaAmerican Journal of Cancer, 2006
- Hematologic Effects of Linezolid: Summary of Clinical ExperienceAntimicrobial Agents and Chemotherapy, 2002
- Suppressive effects of human herpesvirus-6 on thrombopoietin-inducible megakaryocytic colony formation in vitroJournal of General Virology, 2000
- Thrombocytopenia in severe bacterial infectionsJournal of Surgical Research, 1976